Business Context and Reporting Period
Company: Aethlon Medical, Inc. (Nasdaq: AEMD)
Filing Type: Form 8-K (Current Report)
Date of Report: September 17, 2026
Event: Entry into a Material Definitive Agreement for a merger with North Immunology, Inc.
Key Financial Metrics and Transaction Terms
This filing details a proposed merger and reorganization rather than standard periodic financial results. Key transaction metrics include:
- North Immunology Valuation: $150,000,000 equity value (subject to adjustment based on Private Placement proceeds).
- Aethlon Medical Valuation: $16,500,000 (reduced by any net cash deficit at closing).
- Private Placement (PIPE): Approximately $180 million total, consisting of ~$146 million in cash and ~$34 million in convertible promissory notes.
- Pro Forma Ownership: Pre-Merger North Immunology stockholders expected to own ~95.25%; Pre-Merger Aethlon stockholders expected to own ~4.75%.
- Advisory Fees: 591,574 shares of Common Stock issued to Maxim prior to closing.
- Termination Fees: $300,000 payable by Aethlon; $2,000,000 payable by North Immunology under specified circumstances.
Note: The filing does not provide specific revenue, profit, cash flow, or debt figures for the reporting period.
Material Changes and Transaction Structure
The filing announces a significant change in control and corporate structure:
- Merger Mechanics: Aethlon will merge with North Immunology via two merger subsidiaries. North Immunology will survive as a wholly-owned subsidiary before merging into the second subsidiary.
- Corporate Name Change: The combined company will be renamed "North Immunology, Inc."
- Stock Split: A reverse stock split of Aethlon's Common Stock may be implemented to satisfy Nasdaq listing requirements.
- Leadership: The combined company will be led by North Immunology's CEO, with directors and officers designated by North Immunology.
- Legacy Assets: Aethlon's legacy business (including Hemopurifier assets) will be monetized, with proceeds distributed via Contingent Value Rights (CVRs) to pre-merger Aethlon shareholders.
Guidance, Risks, and Contingencies
Conditions to Closing:
- Approval by stockholders of both companies.
- Effectiveness of the Form S-4 registration statement.
- Nasdaq approval of the initial listing application.
- Receipt of at least $175,000,000 from the Private Placement.
- Expiration of Hart-Scott-Rodino waiting periods.
Key Risks and Contingencies:
- CVR Uncertainty: No assurance exists that Aethlon's legacy assets will be monetized; if no proceeds are received, CVR holders receive nothing.
- Transaction Failure: Risks include failure to obtain regulatory approvals, stockholder votes, or financing.
- Exchange Ratio Adjustment: The final exchange ratio depends on Aethlon's net cash position at closing.
- Lock-Up Period: Certain North Immunology insiders are subject to a 180-day lock-up on shares received in the merger.
Investor Verification Checklist
- Verify the final Exchange Ratio once Aethlon's net cash position at closing is determined.
- Confirm the successful closing of the $180 million Private Placement, which is a mandatory condition for the merger.
- Review the upcoming Form S-4 for detailed risk factors and the full text of the Merger Agreement.
- Monitor the status of the Contingent Value Rights (CVRs) and any potential monetization of Aethlon's Hemopurifier assets.
- Check for Nasdaq approval of the initial listing application for the combined entity.